Cristália Produtos Químicos Farmacêuticos Ltda
As of the edition of 20 October 2026, Cristália Produtos Químicos Farmacêuticos Ltda runs 8 drugs, 6 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Pegfilgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Enoxaparin sodium | none listed | 3 |
| Heparin | none listed | 5 |
| Latanoprost | none listed | 5 |
| Sulfadiazine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| PTGFR Prostaglandin F2-alpha receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Cristália Produtos Químicos Farmacêuticos Ltda needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 2 trials led
- Urinary and reproductive: 2 trials led
- Heart and blood vessels: 1 trials led